



Pursuing  
Infinite  
Opportunities

Association of Biotechnology Led Enterprises



# INDIA BIOTECH HANDBOOK 2025



## Your trusted partner for Contract Research and Manufacturing Services

### Expertise in CRO Services

-  Field Trials & Crop Research
-  Soil & Plant Analysis
-  Pesticide & Fertiliser Testing
-  Regulatory & Compliance Support
-  Biotechnology Services



### Expertise in CDMO Services

-  Custom Formulation & Manufacturing
-  Bulk Production & Private Labelling
-  Microbial & Biotech Product Development
-  Seed Treatment & Coating Solutions
-  Agrochemical & Bio-pesticide Manufacturing

**AGRICULTURE | MATERIALS | HEALTHCARE**

For Queries, Contact us at:  
[us@absolute.ag](mailto:us@absolute.ag)

[www.absolute.ag](http://www.absolute.ag)



# CONTENTS

<b>Foreword by ABLE President</b>	<b>04</b>
<b>Overview of Indian BioEconomy</b>	<b>06</b>
<b>India Delegation #BIO2025</b>	<b>24</b>
<b>India Exhibits at BIO Boston 2025 Locator Map</b>	<b>34</b>
<b>Program Schedule</b>	<b>37</b>
<b>ABLE Focus Areas</b>	<b>42</b>
<b>India Pavilion Exhibitor Profiles</b>	<b>45</b>

## Acknowledgements

India Biotech Handbook has been envisioned and published by Narayanan Suresh, Chief Operating Officer, Association of Biotechnology Led Enterprises (ABLE). Co-ordinated and carried out by Ms Pavana Praveen, Manager-BDO & Ms Indrila Sengupta, Asst. Manager-BDO. Designed and printed by Sareeta Sajjan. Dr Balasubramanya S, General Manager is the Chief Coordinator for the INDIA Pavilion@BIO Boston, June 16-19, 2025.

Comments and questions are welcome and should be addressed to:  
 Narayanan Suresh, Chief Operating Officer,  
 Email: [coo@ableindia.org.in](mailto:coo@ableindia.org.in) Website: [www.ableindia.in](http://www.ableindia.in)  
**ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES (ABLE)**  
 No.123/C, 16th Main Road 4th Block, 5th Cross, Koramangala,  
 Bangalore-560034, India. Tel: +91-80-41636853





## From ABLE President's Desk

**G S Krishnan**

**Hon. President - ABLE**

### Greetings from ABLE!

A warm welcome to all the participants from the biotech fraternity in India. I am happy to present to you the snapshots of the best of India's globally acclaimed biotech industry. The products and services from India's 600+ biotech companies and 10,000+ startups have contributed a significant 4.25% to the nation's \$4 trillion Economy that has now emerged as the world's largest economy nudging past Japan.

India's biotech talent is on display yet again at the **"India Pavilion"**, organized every year by ABLE along with DBT/BIRAC at the annual **"US BIO Convention"**. Top 28 biotech companies, innovative startups, some of India's best bio incubators and states that provide immense support to the biotech ecosystem participate.

India Pavilion is not just a showcase of the country's biotech talent, this time at **"BIO Boston"**, it is also at the core of spreading the message to the global community that the country's innovative talent is here, taking up any challenge to solve some of the humanity's urgent needs. The world needs our support as we try to feed, fuel and heal the billions of people.

ABLE has organized a series of activities centred around the BIO Convention. An **Indian**

**Startups Delegation**, organized by ABLE, will undertake a high-impact exploration program at Boston, New York and New Jersey life science and healthcare innovation hubs to explore cross-border innovation and investment opportunities. A special **Interaction Meeting with the Indian Student Diaspora** is organized jointly by ABLE, Nucleate and the Harvard Biotech Club at the Harvard Medical School campus, a valuable platform to connect with the next generation of biotech innovators.

The industry delegation will be visiting one of Boston's acclaimed **Biofoundry setup by Manus Bio** to get firsthand knowledge to replicate this success story as the country embarks to implement the BioE3 Policy, that aims to put India on a global BioManufacturing leadership path. ABLE will also be contributing significantly to the discussions organized by the International Council of Biotech Associations (ICBA) on how to strengthen the biotech global supply chains to prepare for the next pandemic. Indian delegation will also be interacting with the biotech influencers and industry leaders at a select gathering in Boston during the event.

I look forward to an action-packed India Pavilion and the carefully curated activities to provide the world some glimpses into to India's innovative biotech ecosystem. On behalf of ABLE, I welcome you all to show the best we have in biotech.



**Dr. B. Lal Institute  
of Biotechnology**  
An Ekamra Bioscience Institute

# Where Scientific Curiosity Ignites Innovation

## The BIBT Edge: Where Numbers Speak Excellence



**16+**  
Years of  
Excellence



**2000+**  
Alumni  
Network



**100%**  
Placements



**50+**  
Industry and  
Academia  
Collaborations



**250+**  
Research  
Publications



**25+**  
Research Projects Funded by  
International and National  
Foundations

## Advancing Research Through Multidisciplinary Projects



**WASTE WATER  
MANAGEMENT USING  
VERMIFILTRATION**



**ZERO WASTE MODEL  
PROJECT IN AANDHI  
VILLAGE**



**COVID-19 WASTEWATER  
SURVEILLANCE PROJECT**

## BIBT Highlights



State of the Art Lab &  
Instrumentation



Research-driven  
organisation



Industry-focused Curriculum  
& Practical Training



Experienced  
Faculty

**B.Sc. Biotechnology | M.Sc. Biotechnology & Microbiology | PhD**

6-E, Malviya Industrial Area, Malviya Nagar, Jaipur, Rajasthan, 302017

+91 98290 38177

admission@blalbiotech.com

www.blalbiotech.com



## Overall Size & Structure

# BIOECONOMY 2024

India's BioEconomy has witnessed a phenomenal rise over the past decade, transforming from a fledgling sector to a powerhouse contributing significantly to the nation's economic growth. In 2003, India's bioeconomy stood at a modest **\$2 billion**. The initial phase witnessed steady growth, reaching **\$5 billion** by 2008, with the bioeconomy tripling to **\$11 billion** by 2013. This period marked the beginning of a remarkable upsurge.

From 2013 to 2018, the bioeconomy experienced an exponential surge, reaching a staggering **\$55 billion** – a phenomenal **400%** growth. The momentum continued between 2018 and 2024, with the bioeconomy reaching a colossal **\$165.7 billion**.

The state governments are setting targets as a factor of national BioEconomy Values and as part of the Gross State Domestic Product (GSDP) considerations. More about such examples will be shared in subsequent sections.





BIOECONOMY  
VALUE  
**\$165.7 BN**



STARTUPS  
**10,075**



GDP

**\$3.89** TRILLION



CONTRIBUTION  
TO NOMINAL GDP

**4.3%**



# India's BioEconomy Nearly Doubles Over Five Years

India's BioEconomy has showed remarkable growth over the past five years, expanding from **\$86 billion** in 2020 to **\$165.7 billion** in 2024. This represents a **92.7%** increase over the five-year period, highlighting the sector's robust expansion and increasing significance in India's economic landscape. The compound annual growth rate (CAGR) of **17.9%** underscores the sector's dynamic nature and potential for continued advancement in the coming years.





# India's Leading IP Law Firm



Founded in 1994, K&S Partners is India's top tier Intellectual Property (IP) boutique firm, serving clients in all areas of IP. With nearly 200 professionals spread across major Indian cities, we serve a large repertoire of Indian and global corporations, including Fortune 500 companies, research institutes and universities, with a technology-focused approach. Our affiliate Firm, J. Sagar Associates (JSA), is one of the largest corporate commercial firms in India.

## Excellence in Life Sciences IP

- 1 Globally ranked, seasoned patent attorneys with specialized degrees in biotech, chemistry and pharmaceuticals
- 2 Strong expertise in Biodiversity law, Plant Variety Protection law and Trade Secrets

## Sectorial Specializations

- Pharmaceuticals
- Chemicals
- Medical Devices
- Polymers
- Therapeutics
- Cosmetics & FMCG
- Antibody
- Vaccines
- DNA Technology
- Immunotherapy
- Nano-Biotech
- Plant Biotechnology

## Our Services

### Advisory

- Prior art searches, FTO & infringement analysis
- Landscape study and analysis Invalidity opinions

### Protection

- Litigation and contentious proceedings
- Oppositions | Revocations | Infringement actions

### Transactional

- Due diligence in M&A transactions; transactional support and licensing

### Prosecution

- Drafting, filing and prosecution of patent applications

## Wide-ranging Expertise across IP Domains

Patent | Trademark | Litigation | Design | Copyright | Geographic Indications | Biodiversity Laws  
Digital Laws | Plant Variety | Trade Secrets | Semiconductor & Layout | Other Relevant Laws

+91 124 4708 700   info@knspartners.com   www.kandspartners.com

Our Offices: Bengaluru | Chennai | Gurugram | Hyderabad | Mumbai | New Delhi | Pune

## Four key segments contribute to the India BioEconomy

**BIOINDUSTRIAL:** The BioIndustrial sector in India is a significant contributor to the country's BioEconomy. This sector leverages biotechnology to produce a wide range of products using enzymes and microbes which are essential biocatalysts that speed up biochemical reactions. Multiple industries, including Textiles, Alcoholic Beverages, Detergents, Paper & Pulp, Leather, Aquaculture and Poultry, Baking, Starches, and Vegetable Oil, use enzymes in key processes that are now intrinsic to the end products from these sectors. The applications highlight the versatility and importance of enzymes and microbes in the BioIndustrial sector, contributing to sustainable and efficient production processes across various industries.

**BIOPHARMA:** The BioPharma sector is another major driver of India's BioEconomy, encompassing the development and production of pharmaceuticals, vaccines, diagnostics, and medical devices. It has been a leading segment, with diagnostics and therapeutics playing crucial roles. The sector benefits from India's strong gener-

ics market and growing capabilities in biologics and personalized medicine.

**BIOIT/RESEARCH SERVICES/BIOSERVICES:** This segment includes contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and BioIT services. It supports the broader BioEconomy by providing essential research and development services, leveraging India's IT capabilities to enhance biotech innovation and efficiency.

**BIOAGRI:** The BioAgri sector focuses on genetically modified crops, precision agriculture technologies, and bio-based products. It includes notable contributions from Bt Cotton, biopesticides, biofertilisers and biostimulant. This sector plays a vital role in enhancing food security and sustainability in India's agricultural landscape.

These segments collectively contribute to the robust growth and diversification of India's BioEconomy, each playing a unique role in driving innovation and economic development.

## Segment Performance (2023-2024)

Segment	2023	2024	Growth	Growth (%)
BioIndustrial	72.6	78.2	5.6	7.7%
BioPharma	53.8	58.4	4.6	8.6%
BioAgri	12.4	13.5	1.1	8.9%
BioIT/Research Services/ BioServices	12.1	15.6	3.5	28.9%
Total	151.1	165.7	14.6	9.7%

All figures in \$bn

Source: ABLE



Overall BioEconomy Growth Trajectory

\*Totals may not sum to 100% due to rounding to the nearest decimal

All figures in \$bn





## BIOINDUSTRIAL SECTOR

As the largest component of India's BioEconomy, the BioIndustrial sector accounts for 47.2% of the total BioEconomy value in 2024. With a value of \$78.2 billion, this segment has grown by 7.7% from 2023 to 2024. While its growth rate is slightly below the average for the overall BioEconomy, its substantial size means it contributed 47.2% of the total BioEconomy in absolute terms (Or \$5.6 billion of the total \$14.6 billion increase in value). The dominance of this sector reflects India's strong industrial biotechnology foundation, including biofuels, bio-based chemicals, enzymes, and industrial bioprocesses. The moderate but steady growth rate suggests a maturing sector with established applications and technologies.



## BIOPHARMA SECTOR

The BioPharma sector is the second-largest contributor to India's BioEconomy, accounting for 35.2% of the total value in 2024. At \$58.4 billion, this segment has grown by 8.6% (which is 4.6 bn, accounting for 31.5% share of the growth) from 2023, accounting for 31.5% of the overall growth of the BioEconomy.

The substantial share of the BioPharma sector highlights India's position as a significant global player in pharmaceuticals, vaccines, and therapeutic biologics. The sector's growth rate, slightly below the overall average, may reflect the impact of post-pandemic normalization in healthcare spending.



## BIOIT/RESEARCH SERVICES/ BIOSERVICES

Although representing a smaller portion of the BioEconomy at 9.4% (\$15.6 billion), the BioIT/Research Services/BioServices sector demonstrated the highest growth rate of all segments at 28.9% between 2023 and 2024. This exceptional growth contributed 24.0% to the overall BioEconomy expansion, despite the sector's relatively smaller size.

This impressive performance indicates a rapid expansion in bioinformatics, computational biology, contract research services, and other biotechnology support services. The sector's accelerated growth suggests increasing digitalization in biotechnology and growing demand for specialized biotechnology services and research capabilities.



# JASS BIOLOGICS DESIGN CENTER

*One stop solution for biologics plant needs*

We transform visions into reality with our comprehensive feasibility and design solutions. Our expert team conducts feasibility studies based on your available land, ensuring optimal space utilization and cost-effectiveness. We provide a customized equipment list, an Optimized layout, and a streamlined process design to achieve your desired output efficiently. By combining data-driven insights, industry expertise, and end-to-end support, we deliver solutions that maximize productivity and profitability.

Let's build your success together, Contact us today!

## Services Offered



### Design

Feasibility Study, Concept, base and detailed Design



### Tech-transfer

Site to Site, Research to manufacturing, Fit analysis



### Equipment Design

SU & SS Skid, Columns, Vessels, UFDF, Chromatography



### Installation

FAT / SAT and IOQ Execution Services



### Process Design

Strain selection, Mass balance, Process flow diagrams.



### Procurement

Sourcing, vendor selection, RFQ, technical and commercial bid analysis



### Costing

Capex budgeting & estimation  
Research to commercialisation



### Documentation

Batch records, URS, SOPs, IOQ Protocols



### Project Monitoring & Control

Goods inspection, schedule and cost monitoring & control



## BIOAGRI SECTOR

The BioAgri sector accounts for 8.1% of India's BioEconomy in 2024, valued at \$13.5 billion. The sector grew by 8.9% from 2023 to 2024. It contributed 8.1% to the total growth of the BioEconomy.

The performance of this sector reflects ongoing innovations in agricultural biotechnology, including biofertilizers, biopesticides, genetically modified crops and molecular breeding techniques. The growth rate suggests steady adoption of biotechnological solutions in agriculture, which remains a critical sector for India's economy.



India's BioEconomy has demonstrated remarkable resilience and growth, nearly doubling in size from 2020 to 2024. The sector's expansion has been driven primarily by the BioIndustrial and BioPharma segments, which together account for almost 82.4% of the total Bioeconomy value.

The standout performer in terms of growth rate is the BioIT/Research Services/ BioServices sector which grew by 28.9% between 2023 and 2024, indicating a significant shift

towards digitalization and specialized services in biotechnology.

The continued expansion of India's BioEconomy, even as growth rates moderate, suggests a maturing sector that is becoming increasingly integrated into the broader economy. With a CAGR of 17.9% over the past five years, the BioEconomy represents one of the most dynamic sectors in India's economic landscape, with significant potential for continued innovation and growth in the coming years.



# Syngene

## Announcing the Launch of Our Biologics Manufacturing Facility in the US



**4 Production Suites**  
16,000L single use  
bioreactors (SUBs) in the US



**50L → 4KL SUBs**  
Flexible and scalable  
at speed



**50,000L SUBs**  
Global capacity  
across US and India

Syngene International is a global CRDMO trusted by leading pharma and biotech companies for over 30 years. Our 5500+ scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing — making innovation more accessible.

Meet us at booth #3235 at Bio International 2025, Boston

For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com)  
or write to us at [bdc@syngeneintl.com](mailto:bdc@syngeneintl.com)

© 2025 Syngene International Limited, All Rights Reserved.



Scan the QR code  
to learn more

# India's Biotech Startup Ecosystem Surpasses

# 10,000

Milestone in 2024



India's biotech startup sector continues its rapid ascent, with the last three years showcasing exponential growth. Between 2021 and 2024, the cumulative number of biotech startups surged from 5,365 to 10,075—a 88% increase. This rise reflects a consistent upward trajectory since 2016, with a noticeable surge post-2020.

The biotechnology and life sciences sector added 1,390 startups in 2021, followed by 1,776 in 2023, and 1,554 in 2024. This expansion is driven by increased investments, favorable policy shifts, and rising demand


for biotech innovations in healthcare and sustainability. The moving average trend line further highlights this consistent growth. BIRAC's entrepreneurship development and strategy support programs have played a pivotal role.

The COVID-19 pandemic acted as a catalyst, turning attention to biopharma, health-tech, and diagnostics. Investors increasingly recognized biotech as a high-impact sector. Government initiatives and global partnerships have also played pivotal roles in sustaining this momentum.



Indian startups have developed over 800 products and raised more than \$600 million in follow-on funding. However, while 2022 saw 31 deals totaling \$938.8 million, 2023 saw a dip, with only 16 deals worth \$199.6 million. The year 2024 witnessed recovery and is estimated to close at \$700 million with over two dozen deals. On a positive note, the MedTech sector witnessed robust Foreign Direct Investment (FDI) growth, rising from \$370 million in 2022 to \$618 million in 2024. In contrast, FDI in pharmaceuticals dropped from \$2 billion to \$1 billion in the same period, signaling shifting investment priorities.


Despite these fluctuations, the biotech ecosystem remains vibrant, fueled by domestic innovation and strategic global collaborations. The rising startup activity and increased FDI in MedTech position India as a critical player in the global biotech and health-tech sectors.





# Biotech Spread

across various towns and cities



Places having presence of either Biotech companies, Biotech startups, Biorefineries, Biocubators, Bioresearch centers, Bioprocessing centers, BioMedical manufacturers or BioAgri zones.

# PROPRIETARY NOVEL DRUGS

## FACT SHEET



### Locations

Yardley, PA, USA  
Bengaluru, KN, India



### Website

[www.jubilanttx.com](http://www.jubilanttx.com)

## CORPORATE OVERVIEW

A clinical-stage precision therapeutics company advancing potent and selective small molecule medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases

## HIGHLIGHTS



### Differentiated pipeline

Pipeline of novel drugs, discovered in-house and fully owned, under clinical development are geared to provide potential oral medicines that are more efficacious and provide safer treatment alternatives for genetically mutated cancers in patients worldwide who develop resistance or do not respond to existing therapies available in the market.



### Improved therapeutic efficiency

TIBEO (Therapeutic Index and Brain Exposure Optimization) discovery engine validated with proven track record of successful out- licensing partnerships and subsequent large M&A deals.



### Positive signals

JBI-802: Standalone therapy achieved human proof of principle in certain cancer and showed in one lung cancer patient with specific genetic mutation who had exhausted other modes of treatment, a statistically significant tumor shrinkage, with nearly 2 years life-span extension and significantly better quality of life (still under observation). Combination therapy along with approved checkpoint inhibitors expected to produce better outcomes.

## PIPELINE OF NOVEL THERAPIES

Program	Indications	Preclinical	Phase I/II
JBI-802	<b>ET/MPN</b> <i>Specific Mutations IO Resistance NSCLC - A genetically defined subset of lung cancer that is resistant to immunotherapy</i> <i>Post MPN AML - A rare type of leukemia</i>		
JBI-778	NSCLC with EGFR mutation, IDH high grade glioma and ACC Genetically defined subset of lung cancer, brain tumor and head and neck cancer		
PAD4	Autoimmune Diseases and Cancer - Novel first-in-class therapeutics with no immune suppression		

\* Pipeline includes preclinical programs: PAD4 inhibitor for autoimmune diseases such as Rheumatoid Arthritis and PDL1 inhibitor for cancer

## Contribution of Key States

In 2024, Maharashtra leads India's BioEconomy with a value of \$35.45 billion, representing 21.4% of the total BioEconomy value of \$165.7 billion. Karnataka follows closely with \$32.37 billion (19.5%), while Telangana contributes \$19.9 billion (12%). Gujarat adds \$12.9 billion (7.8%), Uttar Pradesh contributes \$11.3 billion (6.8%), Andhra Pradesh \$11.1 billion (6.7%), and Tamil Nadu \$9.9 billion (6%) respectively. The "Others" category, which includes various smaller states, totals \$32.75 billion, accounting for 19.8% of the BioEconomy value. This distribution underscores the regional strengths within India's rapidly growing biotechnology sector, poised for significant expansion in the coming years.

Maharashtra \$35.45 bn

Karnataka \$32.4 bn

Telangana \$19.9 bn

Gujarat \$12.9 bn

Uttar Pradesh \$11.3 bn

Andhra Pradesh \$11.1 bn

Tamil Nadu \$9.9 bn

Others \$32.75 bn



Maharashtra

**21.4%**



Karnataka

**19.5%**



Telangana

**12%**



Gujarat

**7.8%**



Uttar Pradesh

**6.8%**



Andhra Pradesh

**6.7%**



Tamil Nadu

**6%**

Others  
**19.8%**

Total  
BioEconomy Value  
**\$165.7 bn**



# Regional Analysis of the BioEconomy Distribution

India's BioEconomy landscape, valued at approximately \$165.7 billion, exhibits distinct regional patterns that reflect historical investments, policy priorities, and natural resource advantages. These four major regions—South, West, North, and East—house India's BioEconomy activities; each region possesses a unique sectoral composition that defines its market.

The Bioeconomy's four key sectors—BioIndustrial, BioPharma, BioServices, and BioAgri—show significant

variation in regional concentration, revealing specialized ecosystems that have grown through a combination of deliberate strategic focus and organic development. The South leads in business, having a diverse range of companies, while other regions concentrate on specific areas. The regional distributions provide critical insights for policymakers, investors, and industry leaders seeking to identify growth opportunities, address market gaps, and develop strategic partnerships across the bioeconomy landscape.



## SOUTH REGION

(\$75.2 bn, 45.4% share)

- ✓ **Dominant player** in the BioEconomy market
- ✓ Strong leadership in **BioIndustrial** (\$30.0 bn) and **BioPharma** (\$28.7 bn)
- ✓ Exceptional performance in **BioServices** (\$12.5 bn), controlling 80% of this sector
- ✓ Moderate presence in **BioAgri** (\$4.0 bn)
- ✓ Overall balanced portfolio across all segments

## WEST REGION

(\$50.2 billion, 30.3% share)

- ✓ **Second largest** regional market
- ✓ Strong in **BioPharma** (\$25.1 bn) accounting for 43% of this sector
- ✓ Significant presence in **BioIndustrial** (\$14.2 bn)
- ✓ Leading position in **BioAgri** (\$8.2 bn), controlling 61% of this sector
- ✓ Relatively weak in **BioServices** (\$2.7 bn)

## NORTH REGION

(\$30.6 bn, 18.5% share)

- ✓ **Third largest** regional market
- ✓ Significant presence in **BioIndustrial** (\$25.0 bn)
- ✓ Modest presence in **BioPharma** (\$4.1 bn)
- ✓ Very limited activity in **BioAgri** (\$1.2 bn) & **BioServices** (\$0.3 bn)
- ✓ Overall portfolio heavily weighted towards BioIndustrial

## EAST REGION

(\$9.7 bn, 5.8% share)

- ✓ **Smallest** regional player
- ✓ Primarily focused on **BioIndustrial** (\$9.0 bn)
- ✓ Minimal presence in other sectors
- ✓ Represents an emerging or under developed bioeconomy region



## HIGHLIGHTS of BIO 2024





# India Delegation@ #BIO2025



### Shri. Priyank M Kharge

Hon'ble Minister - Rural Development and Panchayat  
Raj and Information Technology & Biotechnology  
Government of Karnataka

#### Kiran Mazumdar-Shaw

Hon. Non-Executive Chairperson, ABLE  
Executive Chairperson and Founder Of  
Biocon Limited &  
Biocon Biologics Limited

#### P M Murali

President,  
Council Of Presidents  
Association Of Biotechnology  
Led Enterprises (ABLE)  
Pmmurali@Ableindia.org.in

#### G S KRISHNAN

Hon. President  
ABLE  
president@ableindia.org.in

#### Jitendra Kumar

Managing Director  
Biotechnology Industry Research  
Assistance Council (BIRAC)  
md@birac.nic.in

#### Prachi Agarwal

Chief Manager  
Technical Department  
Biotechnology Industry Research  
Assistance Council (BIRAC)  
pagarwal@birac.nic.in

#### Zachariah Karunakaran

Associate Vice President  
Guidance Tamil Nadu  
zachariah@investtn.in

#### Ekroop Caur, I.A.S.

Secretary To Government,  
Department Of EI, IT, BT And S&T  
Government of Karnataka

#### Alarmelmangal I.A.S.

Executive Director  
Guidance Tamil Nadu  
Ed@Investtn.in

#### Shri. Rahul Sharanappa Sankanur I.A.S.

Director, Dept. Of E, IT and BT, GoK,  
Managing Director  
Karnataka Innovation and  
Technology Society, GoK

#### Shri. Nithin Chakki, K.A.S

General Manager,  
Events & Promotions and AVGC  
Karnataka Innovation And  
Technology Society, Gok

#### Gopala K Dasika

Strategic Biotech Advisor To GoTN  
Guidance Tamil Nadu  
gopalakdasika@gmail.com

**Narayanan Suresh**  
COO  
Association of Biotechnology  
Led Enterprises (ABLE)  
coo@ableindia.org.in

**Balasubramanya S**  
General Manager  
ABLE  
gm@ableindia.org.in

**Pavana Praveen**  
Manager-Business Development and  
Operations  
ABLE  
pavanapr@ableindia.org.in

**Indrila Sengupta**  
Asst. Manager-Business Development  
and Operations  
ABLE  
indrila@ableindia.org.in

**Poongumaran Panneer Selvam**  
Managing Director  
TICEL Biopark Ltd  
md@ticelbiopark.com

**Senthilkumar Vanarajan**  
Manager - (Scientific / Bioprocess)  
TICEL Biopark Ltd  
scientific@ticelbiopark.com

**Praveen.K.S**  
Chief Executive Officer  
Kerala Life Sciences Industries Park  
ceo@blo360.in

**Sunitha Chandran**  
Senior Manager, Business Development  
Kerala Life Sciences Industries Park  
sunitha@blo360.in

**Fathima Benazir**  
Chief Science Officer  
Azooka Labs Pvt. Ltd.  
drb@azooka.life

**Alex D Paul**  
CEO  
Azooka Labs Pvt. Ltd.  
alx@azooka.life

**Mohamed Adil A. A**  
Managing Director  
Bangalore BioInnovation Centre  
(BBC)  
director@biainnovationcentre.com

**Divya C**  
CEO  
BioAgile Therapeutics Pvt. Ltd.  
divya@bioagiletherapeutics.com

**Shreehas Tambe**  
CEO & MD  
Blocon Biologics Limited  
Shreehas.Tambe@blocon.com

**Dhruv Taneja**  
Associate Vice President - Corporate  
Blocon Biologics Limited  
dhruv.taneja@blocon.com

**Susheel Umesh**  
Chief Commercial Officer -  
Emerging Markets  
Blocon Biologics Limited  
susheelumesh@blocon.com

**Sushanth Boda**  
Senior Director -  
Business Development  
Blocon Biologics Limited  
sushanth.boda@blocon.com






# Centre For Incubation, Innovation, Research and Consultancy

(Scientific and Industrial Research Organization Recognized by DSIR, Govt)

Website: [www.ciirc.res.in](http://www.ciirc.res.in)

Email: [info@ciirc.res.in](mailto:info@ciirc.res.in)

## Research Labs / Areas



## Success Stories



Artis (North India) Hissail station (PT)



41st Indian Scientific Expedition to Antarctica - Jan-2012



Runway Visual Ranging (BSL) for Design, Plan, Assess, Review, Announce Products



NISTC Westwood for detecting non-susceptible drug products



Bangalore, Tamil Nadu, India-2012

## Instruments / Facilities

SEM, XRD, HPLC, GC, BET, DSC, TGA, FTIR, 3D Printer, Fluorescence microscope, Stereo microscope, RT-PCR, Multinucleotide reader, Fermenter, BSL-2, Gel Doc system, Protein purification system, Kjeldhal system, Live cell imaging scanner, Plant tissue culture, Green house and animal cell culture.

## Funded Projects

International Funded Projects - Indo-Sweden, Indo-Belarus, Indo-Egypt, Indo-France, Indo-ASEAN and European Union.

National Funded Projects - DST, DBT, DRDO, DOS, UGC-DAE, MOES, DIC-KCTU, VGST, AYUSH and KSSRDI

## CIIRC Supported Products

### Fostering Solutions from Mother Nature



### Bio-products developed from Crop residues and Biomass



### Millets and Hydrocolloid Enriched Health Drinks



**Stephanle Wasco**  
Head of Communications,  
Advanced Markets  
Blocon Biologics Limited  
stephanle.wasco@blocon.com

**Lance Longwell**  
PR Lead, Advanced Markets  
Blocon Biologics Limited  
lance.longwell@blocon.com

**ALN Reddy**  
Sr Vice President  
Biological E. Limited  
Reddy.ALN@biological.com

**N Mantena**  
Director  
Biological E. Limited  
nmantena@biological.com

**Ganesh Mishra**  
Asst. General Manager  
Biological E. Limited  
Ganesh.Mishra@biological.com

**Venkata Ramireddy Yeturu**  
Associate President - Program  
Management and Business  
Development  
CuraTeQ Biologics  
venkat.yeturu@curateqblo.com

**Paresh Patel**  
Vice President- Business Development  
& Operations  
CuraTeQ Biologics  
paresh.patel@curateqblo.com

**Nusrat J M Sanghamitra**  
Founder & C.E.O  
CyGenica Limited  
nusrat@cygenica.com

**Fazlul H Krishnan**  
Co-Founder & Director Operations  
CyGenica Limited  
fazlul@cygenica.com

**Rajanikanth Rau**  
Sr Vice President  
Biological E. Limited  
Rajanikanth.Rau@biological.com

**Deepa Arora**  
Chief Executive Officer  
Clinexel Life Sciences Pvt. Ltd.  
deepaarora@clinexel.com

**Mukesh Kumar**  
Chief Executive Officer  
Clinexel Life Sciences Pvt. Ltd.  
mukesh@clinexel.com

**Pradyumna Mulpur**  
Deputy General Manager - Program  
Management and Business  
Development  
CuraTeQ Biologics  
pradyumna.mulpur@curateqblo.com

**Harish S**  
Director  
ICBio Clinical Research Pvt. Ltd.  
harish@icbiocro.com

**Pushpa Latha G**  
Director  
ICBio Clinical Research Pvt. Ltd.  
Info@icbiocro.com

**Viswanadham Duppatla**  
VP - Biopharma Innovation &  
Biomanufacturing  
IKP Knowledge Park  
viswanadham@ikpknowledgepark.com

SCALE SMARTER SAFER

# MAYAI

By ProductDev Edge

A **GenAI** PLATFORM FOR COSMETIC RESEARCH & DEVELOPMENT

Patented Formulation Model

## Do you want to launch your product 50% faster?



Virtually prototype  
your formulas in

# 2

Minutes

Custom formula  
generation

Minimize your lab trials

# 50%

Reduction  
in cost & time



# >3

Formulas  
Formula/Week/Resource



# >36

Innovative products  
Launch/Year/Resource

Email :[info@productdevedge.com](mailto:info@productdevedge.com); [simi.sugathan@productdevedge.com](mailto:simi.sugathan@productdevedge.com)

<https://productdevedge.com>



**Sanjay Sarin**  
Chief Executive Officer  
IKP Knowledge Park  
sanjay.sarin@ikpknowledgepark.com

**Sudarsana Reddy**  
CEO  
Oncosmils Biotech  
IKP Knowledge Park  
sreddy@oncosmils.com

**Sarthak Vasudeva**  
VP and Head-  
International Business  
Indian Immunologicals Ltd.  
v.sarthak@indimmune.com

**Anand Kumar**  
Managing Director  
Indian Immunologicals Ltd.  
anandkumar@indimmune.com

**Anand Prasad**  
Assistant Vice President, Sector Lead  
(Pharmaceuticals & BioTechnology)  
Invest India  
anand.prasad@investindia.org.in

**Tarun Khurana**  
Partner  
Khurana & Khurana,  
Advocates and IP Attorneys  
Tarun@khuranaandkhurana.com

**Raveesh Malik**  
Manager  
Biotechnology & Pharmaceuticals  
Invest India  
raveesh.malik@investindia.org.in

**TS Sharat**  
Partner  
Khurana & Khurana,  
Advocates and IP Attorneys  
Sharat@iprd.com

**Jagdish Patankar**  
Co-Founder & Exec Chairman  
MM Activ Sci-Tech Communications  
jagdish.patankar@mmactiv.com

**Rajeev M Patil**  
Head  
Bio-Studies Norwich  
Clinical Services Pvt. Ltd.  
rajeev.patil@norwichclinical.com

**Anuradha Manlyam**  
Principal  
Padmashree Institute of Management &  
Sciences  
plmsprincipal@gmail.com

**Abhinav Sabharwal**  
CEO  
Pharmaffiliates Analytics &  
Synthetics Pvt. Ltd.  
mktg@pharmaffiliates.com

**Mayukh Mukherjee**  
AGM, BD  
Pharmaffiliates Analytics &  
Synthetics Pvt. Ltd.  
mayukh@pharmaffiliates.com

**Darshit Mehta**  
Vice President of Programs  
PopVax Pvt. Ltd.  
darshit@popvax.com

**Seema Mittal**  
Program Director- Innovation and  
Outreach  
Prescience InSilico Pvt. Ltd.  
seema@prescience.in





**Alswarya Pawar**  
Team Lead- Life Science  
Prescience InSilico Pvt. Ltd.  
alswarya@prescience.in



# Reimagining the Future of Multi-Omics

Uncoded is your partner in pioneering scientific discovery delivering next-gen, Made-in-India NGS panels and multi-omics kits that are designed for affordability, scalability, and impact.



-  In-House R&D
-  Affordable Pricing
-  Customization
-  Scientist-Led Brand

Follow us for know more



LinkedIn



Website

Powered by



E-49/5, Second floor, Okhla Phase II,  
Delhi - 110020



[uncoded@premaslifesciences.com](mailto:uncoded@premaslifesciences.com)



+91-11-46170798

**Velkumar Bahulayan**  
Chief Operating Officer  
Prescience InSilico Pvt. Ltd.  
velkumar@prescience.in

**Bala Reddy**  
Founder & Director  
Provis Biolabs  
balareddy@provisbiolabs.com

**Ravi Vinayak**  
Business Development Head  
Provis Biolabs  
bdusa@provisbiolabs.com

**Amod Kulkarni**  
Technical Specialist  
Provis Biolabs  
amoduct@gmail.com

**Chirag Shah**  
Head - Clinical Operations  
Raptim Research Limited  
chirag.shah@raptimresearch.com

**Abhinav Dhandia** CEO  
SPHAERA PHARMA  
abhinav.d@sphaerapharma.com

**Madhav Bhutada**  
MD & Promotor  
Shilpa Biologicals Pvt. Ltd.  
madhav@vbshilpa.com

**Sridevi Khambampaty**  
CEO  
Shilpa Biologicals Pvt. Ltd.  
sridevi@shilpablo.com

**Ajay Babu Gopaluni**  
General Manager  
Shilpa Biologicals Pvt. Ltd.  
ajay.gopaluni@shilpablo.com

**Shritya Khandwe**  
Vice president  
Shilpa Biologicals Pvt. Ltd.  
shritya.k@vbshilpa.com

**Andrew George**  
Sr. Manager  
Shilpa Biologicals Pvt. Ltd.  
andrew.g@shilpablo.com

**Hetal Gandhi**  
Director  
Shilpa Biologicals Pvt. Ltd.  
hetaig2005@gmail.com

**Pradeep Dhal**  
Advisor  
Shilpa Biologicals Pvt. Ltd.  
pradeepdhal@vbshilpa.com

**Shantanu Patil**  
Director,  
Directorate of Entrepreneurship &  
Innovation  
SRM Institute of Science and  
Technology (SRMIST)  
director.del@srmist.edu.in

**Saurabh Kapure**  
Chief Executive Officer  
SynSmart Rasayan Research  
saurabh.kapure@synsmart.in

**Srinivasan Parthiban**  
Director, Center for AI in Medicine  
(C-AIM) Vinayaka Missions Research  
Foundation (VMRF)  
parthi@vinayakamissions.com

**Suresh Samuel**  
Chief Strategy Officer  
Vinayaka Missions Research Founda-  
tion (VMRF)  
suresh.samuel@vinayakamissions.com



**Chandrashekar Siddamaddappa**  
Chairman and Managing Director  
Vipragen Biosciences Pvt. Ltd.  
chandra@vipragen.com

**Ramakrishna Dasoju**  
Associate Vice President  
Business Development  
Vipragen Biosciences Pvt. Ltd.  
ramakrishna.d@vipragen.com

**Ashok Malavalli**  
Vice President  
Business Development  
(North America)  
Vipragen Biosciences Pvt. Ltd.  
ashok.m@vipragen.com

**Markandeya Gorantla**  
CMD  
ATGC Biotech  
mg@atgc.in

**Uday Saxena**  
Co-Founder and chairman  
Utopia  
usaxena08@gmail.com



**Gopi Kadiyala**  
CEO, Utopia  
Utopia  
gopi.kadiyala@utoplathx.com

**Rolando Alegria**  
CEO  
ATGC Biotech  
ralegrla@atgc.com

**Raj Bhanushali**  
Owner  
Yashraj Biotechnology Limited  
raj@yashraj.com

**Amit Khanna**  
Head R&D  
Integrated Drug Discovery  
and Development  
Yashraj Biotechnology Limited  
amit.khanna@yashraj.com

## INDIA EXHIBITS AT BIO BOSTON 2025 LOCATOR



Exhibitors	Booth No.
Association of Biotechnology Led Enterprises (ABLE)	973 & 1065
Biological E. Limited	973-A01
Shilpa Biologicals Pvt. Ltd.	973-B01
Pharmaffiliates Analytics & Synthetics Pvt. Ltd.	973-D
Blocon Biologics Limited	1065-A01
Indian Immunologicals Ltd.	1065-A02
Biotechnology Industry Research Assistance Council (BIRAC)	1065-A03
Karnataka Innovation & Technology Society, Department of Electronics, IT & Bt, Government of Karnataka	1065-A04
CuraTeQ Biologics	1065-A05
Government of Tamil Nadu - Guidance & TICEL Bio Park Limited	1065-A06
IKP Knowledge Park	1065-B01
ICBio Clinical Research Pvt. Ltd.	1065-B02
BioAgile Therapeutics Pvt. Ltd.	1065-C01
Bio 360 Life Sciences Park	1065-C02
Khurana & Khurana, Advocates and IP Attorneys	1065-C03
Azooka Labs Pvt. Ltd.	1065-C04
WT Faba Biocatalyst LLP	1065-C05
SRM Institute of Science and Technology (SRMIST)	1065-C06



<b>Vipragen Biosciences Pvt. Ltd.</b>	1065-C07
<b>PopVax Pvt. Ltd.</b>	1065-C08
<b>ClInxel Life Sciences Pvt. Ltd.</b>	1065-C09
<b>SynSmart Rasayan Research</b>	1065-C10
<b>Prescience InSilico Pvt. Ltd.</b>	1065-C11
<b>CyGenica Limited</b>	1065-C12
<b>Bangalore BioInnovation Centre (BBC)</b>	1065-C13
<b>Vinayaka Missions Research Foundation (VMRF)</b>	1065-C14
<b>Yashraj Biotechnology Limited</b>	1065-C15
<b>Provis Biolabs</b>	1065-C16
<b>Raptim Research Limited</b>	1065
<b>SPHAERA PHARMA</b>	1065

# 2025 Program

## **India Pavillion Inauguration**

**Booth 973 & 1065**

**June 16, 2025 | 12.30 Hrs**

### **Shri. Priyank M Kharge**

Hon'ble Minister - Rural Development and  
Panchayat Raj and Information Technology & Biotechnology  
Government of Karnataka

### **Dr. Kiran Mazumdar-Shaw**

Hon. Non-Executive Chairperson, ABLE  
and Executive Chairperson & Founder,  
Biocon Limited & Biocon Biologics Limited

### **Dr. Jitendra Kumar**

Managing Director, Biotechnology Industry Research  
Assistance Council (BIRAC)

### **Mr. G S Krishnan**

Hon. President, ABLE



Scan the QR Code to access  
BIO Schedule

# SPHAERA

Innovation for Patients

Collaborative  
Drug  
Discovery

Diverse  
Therapeutic  
Areas

Integrated  
R&D  
Infrastructure

Proprietary  
Platform  
Technologies

We're a specialized drug discovery and development group, bringing together integrated research capabilities and a highly skilled team. By blending collaborative partnerships with our drug discovery know-how, we efficiently and rapidly advance promising preclinical drug candidates in the most optimum manner.

MEDICINAL CHEMISTRY | PHARMACOLOGY - *IN-VIVO* & *IN-VITRO* | DMPK | ANALYTICAL

- NCE design & synthesis
- Advanced bio-analytical capabilities
- Customized animal efficacy models
- Process chemistry (multi-gram)
- Disease specific in-vitro assays
- PK/ADME and screening tox



**SPHAERA PHARMA**

[www.sphaerapharma.com](http://www.sphaerapharma.com) | [bd@sphaerapharma.com](mailto:bd@sphaerapharma.com)

INDIA - US



BIo International Convention 2025  
June 16 - 19, 2025 | Boston Convention & Exhibition Center

Upper Level - Restaurants and Souvenir Booths



**ABLE INDIA**

HALL/BOOTH NO- 1065 / 973

STAND ORIENTATION

Sathguru Management Consultants



## Sector Expertise Nurtured Over Four Decades

### 40 years of experience

- Established in 1985
- Strong network across C-suite & functional leaders
- Industry depth & perspective honed with experience

### Global network & perspective

- Offices in India, USA
- Experience & network across Asia, Europe, Latin America, MENA
- People Advantage - In-house multi-disciplinary team of 200+

Market leading presence across domains of life sciences – synergistically combining strategy and execution.

Preferred advisor for leading pharma companies, investors and policy makers.

Strategy & Growth

ESG

Innovation & Tech Transfer

Venture Capital

Investment Banking

Policy & Development

## Indicative engagements

### Strategy:

- Peptides market entry strategy for top 5 pharma companies
- Nutraceutical segment strategy & buy-side transaction advisory for Berkshire Hathaway company

### M&A and Investor Advisory:

- Buy-side transaction advisory for listed pharma company in CRO & CDMO segment
- Segment strategy & buy-side for marquee PE fund with > \$48n AUM

### Innovation and tech transfer:

- mAbs – global and regional licensing for listed Indian pharma company
- CNS portfolio out licensing for listed pharma company

### ESG:

- Biotransformation strategy for fragrances and flavors company
- Sustainability impact of regional manufacturing in Africa

## Clients & Partners



Hyderabad, India- Boston, USA || [lifesciences@sathguru.com](mailto:lifesciences@sathguru.com) || [www.sathguru.com](http://www.sathguru.com)

# FOCUS AREAS



**Inputs for  
Streamlining  
Regulatory  
Process**



**Inputs for  
Accelerating  
BioEconomy  
through Advocacy**



**Industry  
Recommendations  
for the Union Budget  
for the Biotech Sector**



**Proposing Fiscal  
Incentives for  
Biotech Sector**



**Strengthening  
IPR System**



**Proactive Member  
Focus Initiatives**



**Catalysing  
Opportunities for  
Start-ups and SMEs**



**Proposals for  
Venture Capital  
Fund**



**Kindling & Fostering  
the Fire of  
Entrepreneurship**



**Encouraging the  
Biotech Sector  
through Investment**



**Facilitating  
Partnership  
through Industry,  
Academia & Start-up**



**Promoting more  
Incubators in  
Biotech Clusters**



**Working Closely with  
the State Government  
& Identify Potential  
Opportunities for  
Biotech Development**



**Promoting  
Entrepreneurship &  
Imparting Skill  
development for  
freshers in Biotech**



**Support Student  
Internship  
Programs &  
Facilitate Placement**



**Promoting Biotech  
among Budding  
Biotech Students  
through various  
Competitions**





R. K. DEWAN & Co.

ADVOCATES, TRADE MARK  
& PATENT ATTORNEYS



# PROTECTING TOMORROW'S BIOTECH BREAKTHROUGHS TODAY

*For more than 82 years, R.K. Dewan & Co. has stood at the forefront of India's intellectual-property landscape. An ISO 9001:2015-certified firm headquartered in Mumbai with six offices nationwide, we combine deep technical insight with a legal pedigree dating back to 1942. Today, we leverage that legacy to safeguard the innovations powering the life-sciences and biotech sectors.*

## WHY CHOOSE US?

REACH US AT:

[www.rkdewan.com](http://www.rkdewan.com)

[dewan@rkdewanmail.com](mailto:dewan@rkdewanmail.com)

# LEADING **INDIA'S IP EVOLUTION** WITH EXPERTISE AND INTEGRITY

## OUR SERVICE SPECTRUM:

- PATENT SEARCH & ANALYSIS, DRAFTING, FILING & PROSECUTION
- PLANT VARIETY PROTECTION
- TRADEMARKS, DESIGNS & COPYRIGHT
- IP AUDITS, VALUATION & COMMERCIALIZATION
- ANTI-COUNTERFEITING & CYBER-FRAUD LITIGATION

## OUR DIFFERENTIATORS:



**Innovative Solutions**



**Recognized Expertise**



**Legacy & Leadership**



**Client Centric Solutions**



**Agile Digital Integration**



**Global Reach, Local  
Insight**

**LIFE-SCIENCE PATENT EXPERTISE | PLANT-VARIETY & BIODIVERSITY  
RIGHTS | TRADE SECRETS & TECHNOLOGY TRANSFER | END-TO-  
END IP LITIGATION**

**LOCATE US:**

**MUMBAI | PUNE | NEW DELHI (NOIDA) CHENNAI | KOLKATA | INDORE**








# India Pavilion Exhibitors



azooka

## METAGENOMICS SAMPLE COLLECTION KITS



**Your  
Manufacturing  
Partner in India**  
Reliable Plan B to China

- Free Global Shipping & Warranty
- OEM & White-Label Solutions
- 40+ Genomics-Grade Consumables

### CONSUMER



Skin Sample - Patch/Swabs  
Ocular Samples Kits  
Fecal Sample Kits  
Sperm Stabilization Kits  
Saliva Sample Kits

### CLINICAL



Blood and CF-DNA  
Exome Samples  
NGS and WGS Kits  
Urine Sample Kits  
Vaginal Sample Kits

### GENOMICS TWIN



Full Genomics Workflow  
Support  
Custom kits for multiomics,  
spatial genomics, and  
microbiome  
For large scale Biorepository

hello@azooka.life

+91 8088747968

www.azooka.life



## BANGALORE BIOINNOVATION CENTRE

HELIX BIOTECH PARK, ELECTRONIC CITY PHASE 1,  
BENGALURU 560100, INDIA



SCAN HERE



website



Brochure

### Why Should International Researchers & Startups Choose BBC?

- ☒ Soft Landing & Market Entry Support
- ☒ Funding & Investment Opportunities
- ☒ Research Collaboration & Technology Transfer Support
- ☒ Business Development & Industry Connect
- ☒ Regulatory & Compliance Support
- ☒ Dedicated Mentorship & Capacity Building
- ☒ Pilot Testing & Clinical Validation Support
- ☒ Cross Border Innovation & Global Networking



Bangalore BioInnovation Centre - 85,000 sq ft



Agri Precision Innovation Centre - 1,80,00 sq ft

### INFRASTRUCTURE & FACILITIES

- ☒ Building & Infrastructure  
28,000 Sq. Ft. & 1,80,000 Sq. Ft.
- ☒ PLAS & PLETHOODULAR LABS & INCUBATION CLIMES
- ☒ CDMO FACILITY
- ☒ CRO FACILITY

### CENTRAL RESEARCH FACILITIES

- ☒ ANALYTICAL FACILITY
- ☒ FERMENTATION FACILITY (UPSTREAM & DOWNSTREAM)
- ☒ GMP FACILITY
- ☒ CLEAN ROOMS
- ☒ DROSOPHILA & ANIMAL FACILITY
- ☒ HIGH END IMAGING FACILITY
- ☒ BIOBANK FACILITY (PROSPECTIVE)
- ☒ SEQUENCING FACILITY
- ☒ FLOWCYTOMETRY & HIGH THROUGHPUT SCREENING
- ☒ BIOPHARMA FACILITY
- ☒ MICROFLUIDICS & MICROFABRICATION FACILITY
- ☒ BIOLOGICS & ADVANCE THERAPY FACILITY
- ☒ STARTUP MANUFACTURING & AUTOMATION FOR MEDICAL SERVICE

### MEDTECH FACILITIES

- ☒ BIO AI & SAAS
- ☒ BIOELECTRONICS MANUFACTURING FACILITY
- ☒ ML & ROBOTICS
- ☒ FABRICATION FACILITY
- ☒ BIO UAV & DRONE FACILITY
- ☒ ASTR SIMULATION FACILITY
- ☒ ML & ROBOTICS





# BIO 360 LIFE SCIENCES PARK

ONE STOP DESTINATION FOR LIFE SCIENCES INDUSTRIES

## UNIQUE ADVANTAGES

Bio 360 Life Sciences Park ,Govt. of Kerala, India

- Leasable plots/built-up space
- State of the art lab infrastructure
- Proximity with R&D institutions
- International seaport (60 Min)- India's first deep-water container transshipment port
- International airport (30 Min)

## Industries We Serve

- |                      |                   |
|----------------------|-------------------|
| ✓ Biotechnology      | ✓ Medical Devices |
| ✓ Pharmaceuticals    | ✓ Nutraceuticals  |
| ✓ Genomics           | ✓ Ayurveda        |
| ✓ Veterinary Science | ✓ Microbiome      |

## IN HOUSE ATTRACTIONS

- Institute of Advanced Virology
- Veterinary University
- Animal House
- Medical Devices Park
- Biotech Incubation Centre
- Prototyping Lab
- Centralized Evaluation facility
- Knowledge Resource Centre
- Business Centre
- Skilled & Trained Interns Available



www.bio360.in



Location Tag



**BIO 360 Life Sciences Park,  
Trivandrum, Kerala, India**



**Tel: +91 471 2991150  
Mob: +91 91889112071**



**klip@bio360.in**

BioAgile Therapeutics Pvt. Ltd. is a full-service Clinical Research Organization (CRO) headquartered in India, established in 2016 with a commitment to delivering high-quality, ethical, and scientifically sound clinical research solutions. We provide end-to-end clinical development services for the pharmaceutical, nutraceutical, biotech, herbal, cosmetics, and medical device industries, supporting studies from Phase I to Phase IV. Our proficiency spans safety, efficacy, and label claims assessment.

Our core services include medical writing, project management, data management, site management, and biostatistics. We offer regulatory-compliant documentation, efficient project coordination, high-quality databases, robust site support, and advanced statistical analyses to ensure the integrity and success of each study.

We collaborate with a wide network of experienced investigators and clinical sites across India, allowing us to conduct trials across diverse therapeutic areas including cardiology, oncology, neurology, dermatology, respiratory, and infectious diseases.

Since inception, we have successfully completed over 120 clinical studies, published 30+ scientific articles, and served more than 50 global clients. With a strong focus on quality, compliance, and client satisfaction, BioAgile Therapeutics remains dedicated to accelerating innovation and supporting the development of safe and effective healthcare solutions worldwide.

For more information, please visit  
[www.bioagiletherapeutics.com](http://www.bioagiletherapeutics.com)



## Enabling access to high quality, affordable biologics globally

We have a growing portfolio of biosimilars, including Insulins, recombinant proteins, and monoclonal antibodies. Our global scale manufacturing facilities with high standards of quality and compliance produce life-improving medicines spanning therapy areas such as diabetes, oncology, immunology, bone health and ophthalmology.

**20** biosimilars approved  
or in development

**120+** countries where our  
biosimilars are available

**9** biosimilars launched  
across global markets

**5+M** patients served globally by  
our biosimilars



[www.bioconbiologicsus.com](http://www.bioconbiologicsus.com)

Data updated as of April 2, 2025





**Biological E. Limited**

*Celebrating Life Every Day*

## SAFEGUARDING LIVES, TRANSFORMING HEALTH, AND SPREADING JOY

- ▶ A pioneer in vaccine & biopharmaceutical manufacturing since 1953
- ▶ End-to-end biologics expertise, including mAbs, backed by proven capabilities
- ▶ Full spectrum of CDMO services in both DS & DP across vaccines & biologics, and complex DP formulations.

### EXPERTISE



PROCESS DEVELOPMENT



GMP & CLINICAL TRIAL MANUFACTURING



FORMULATION / FILL FINISH



PACKAGING & STORAGE



QUALITY CONTROL



**PARTNERSHIP BRINGS  
SUCCESS**

### REGULATORY APPROVAL



U.S. FOOD & DRUG  
ADMINISTRATION



EUROPEAN MEDICAL  
DEVICE AGENCY



World Health  
Organization



Therapeutic Goods  
Administration

TGA

Health  
Department



Medicines  
Healthcare  
Regulatory  
Agency

A Government of India Enterprise, Under Department of Biotechnology  
Ministry of Science & Technology, Government of India

## BIRAC : Enabling Growth of Indian BioEconomy

**Biotechnology Industry Research Assistance Council (BIRAC)** is a not for profit, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Government of India. It is an Interface Agency to strengthen and empower the emerging Biotech ecosystem.

### HOLISTIC SUPPORT FOR ECOSYSTEM



### 13+ YEARS OF IMPACT



### BIRAC FUELS BIOTECH BREAKTHROUGHS, TURNING IDEAS INTO IMPACT

#### India's BioEconomy (2014-24)

(In Billion US\$)



#### Biotech Startup Growth

20x Growth in a Decade



#### BIRAC Programmes and Schemes Provide Support Across Product Development Cycle





## Efficient Drug Development – Pre-IND to Global Clinical Trials

### Our Services

#### Clinical Trials - Full Service End-to-End Execution

- Protocol Design & Development
- Global Clinical Strategy
- Clinical Project Management
- Medical Monitoring
- Site Monitoring
- Site Identification
- Data Management and Statistics
- CSR Writing

#### Clinical Development & Regulatory Affairs

- Pre-IND / Scientific Advice
- Clinical Trial Application / IND
- Clinical Path – Clinical Trial Waivers

#### Pharmacovigilance & Post – Marketing Surveillance

- Safety Management in Clinical Trials
- Post – Marketing Studies
- Pharmacovigilance Operations

### Our Expertise is Across Categories of Products



#### Global GCP Compliant Clinical Trial Execution

- ✓ Solid track record of conducting clinical trials across all 4 phases

#### Phases of Clinical Trials



#### CLINEXEL-Clinical Trial End to End Execution Including Regulatory Negotiations

- ✓ Clinical trials for product registration in India
- ✓ Clinical trials for export or global product registration (India data for US, EU, ROW registration)
- ✓ Clinical Trials in EU, US, Australia, China, India, and Africa
- ✓ AICROS full member- leveraging local presence of AICROS members



Member of AICROS  
since July 2020  
([www.aicros.com](http://www.aicros.com))



#### Value added strengths in Clinical Trials

- Cost efficiencies (cost and time) by using optimization levers
- Design efficient protocol and support regulatory negotiations
- Regulatory Negotiations → Expertise & Experience Across 505(b)(1), 505(b)(2)/Hybrid Applications, & Complex Generics – Inhalation, Dermatology, & Ophthalmic Generics



Dr. Deepa Arora, MD  
City Executive Officer  
(Ex. Vice President, Global Head – India Limited, Indian Pharma & CROs)



Dr. Mahesh Kumar, MD  
Chief Scientific Officer  
(Ex. Sr. Vice President - Dr. Reddy's Lab, CROs)  
Clinical Research Director, Global R&D – Sanofi, Daiichi Sankyo



CDSCO Certified



ISO 9001:2015 QMS  
ISO 27001:2022 ISMS



1401, The Affairs, Bandra, New Mumbai, India-400705 |  
481 Hackensack Ave, Hackensack, NJ 07601, United States



[info@clinexel.com](mailto:info@clinexel.com)









## Improving access to biosimilars for patients across the globe

CuraTeQ Biologics (a wholly owned subsidiary of Aurobindo Pharma Ltd.) is a biopharmaceutical company based out of Hyderabad, India. Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them access to high quality and cost-effective biosimilars.




### Product Pipeline and Approvals

-  Development pipeline of 14 biosimilars with focus on oncology, immunology, and respiratory segments
-  EU GMP compliance certification for mammalian and microbial drug substance and drug product manufacturing unit located in Hyderabad, India
- **BEVQOLVA<sup>®</sup>** (Bevacizumab biosimilar) has received UK MHRA marketing approval
- **ZEFYLT<sup>®</sup>** (Filgrastim biosimilar) and **DYRUPEG<sup>®</sup>** (Pegfilgrastim biosimilar) have received EMA marketing approval
- **DAZUBLYS<sup>®</sup>** (Trastuzumab biosimilar) has received CHMP positive opinion and CDSCO (India) marketing approval

### Development Capabilities

-  State-of-the-art R&D Centre with footprint of 33,000 sq. ft.
-  Over 125 scientists (PhDs to Masters ratio of 1:5) with expertise in clone, process, and method development for small proteins to complex monoclonal antibodies


### cGMP Capabilities

-  **EU GMP Certified** 140,000 sq. ft. multi-product facility for manufacturing, warehousing, packaging, and labeling
-  Designated sections for manufacturing microbial and mammalian bulk drug substance (DS)
-  Segregated suites for drug product (DP) filling in vials, pre-fillable syringes, and cartridges



**CuraTeQ Biologics (Manufacturing Site)**  
Survey No. 77 & 78, Indrakaran Village,  
Kandi Mandal, Sangareddy District,  
Hyderabad, Telangana - 502329, India

[www.curateqbio.com](http://www.curateqbio.com) | [info@curateqbio.com](mailto:info@curateqbio.com)



## Rewriting the Intracellular Delivery Mechanism for Biologics and Beyond

CyGenica is a deep science biotech startup transforming intracellular delivery with GEENIE, a patented, first-in-class protein nanoneedle. Unlike viral vectors or lipid nanoparticles, GEENIE enables non-toxic, endosome-free delivery of siRNA, ASOs, proteins, and gene editors directly into the cytoplasm. This breakthrough platform shows superior performance across liver, brain, and ocular models offering a powerful alternative for treating previously intractable diseases. With strong proof-of-concept data and a non-toxic profile in vivo, CyGenica is forging strategic partnerships with global pharmaceutical leaders to co-develop next-generation therapies and building a globally competitive drug delivery platform.

To collaborate or learn more, visit  
[www.cygenica.com](http://www.cygenica.com)

CYGENICA

**K-tech**



**INNOVATE  
KARNATAKA**



BT Policy

# Karnataka

## A Biotech Frontrunner

### Karnataka BioEconomy 2025

Valuation of  
Karnataka  
Bio Economy  
(\$bn)

**\$32.4**

States  
contribution  
to India  
Bioeconomy (%)

**19.5%**

Biotech  
startups  
in the state

**1,232**

R&D  
investments  
of the state  
(mn) approx.

**\$300**



Glance through Biotech  
Ecosystem in Karnataka



GIA - To explore  
global collaboration

#### Centres ready for joint initiatives



CoE  
**Agri Innovation**



CoE  
**Aquamarine**



CoE  
**Healthtech & Medtech**

**Join  
THE BIOTECH  
REVOLUTION in  
KARNATAKA**

+91 8022231008 / 22231006  
itbtsec@karnataka.gov.in  
@ITBTGoK  
www.itbtst.karnataka.gov.in  
www.missionstartupkarnataka.org

Karnataka Innovation and  
Technology Society (KITS),  
BKG Sapphire, #59,  
Railway Parallel Road,  
Kumara Park West,  
Bengaluru 560020





## ICBio Clinical Research

An independent full-service Contract Research Organization(CRO), INDIA,  
delivering high-quality, end-to-end clinical research solutions,  
**Bio-availability / Bio-equivalence Studies & Clinical Trials Phase I – IV**



*World-class BE facilities adhering to highest compliance with data integrity, quality & safety. 132-bed facility across 4 CPUs facility with Bio-analytical testing services, GCP, GLP & 21 CFR Part-11 compliant CRO.*

### ICBio- One Stop Solutions for Global Reach

Global  
**56**  
countries  
around the globe

**70** Plus Staff  
members

#### Experience with Route of administration

**Injection**

**Rectal**

**Oral**

**Transdermal**

**Vaginal**

**Pulmonary**

- Tablet (IR, ER, DR, OD, EC)
- Capsule (Soft Gel, MR)
- Chewable Tablets
- Suspension
- Granules
- Sublingual

**1000+**  
RA/BE Studies

**7+** Physicians

**80+** Satisfied  
clients

**500+**  
trials supported

**7**  
Accreditation  
and certification

**20+**  
Therapeutic areas

[info@icbiocro.com](mailto:info@icbiocro.com)

[www.icbiocro.com](http://www.icbiocro.com)

[+91 9900111997](tel:+919900111997)



## IKP Knowledge Park: Catalyzing Innovation from India's Genome Valley

IKP Knowledge Park is a pioneering science park and incubator located in Genome Valley, Hyderabad, India's first organized cluster for life sciences R&D and clean manufacturing. Dedicated to nurturing innovation in deep science and technology, IKP has, over the past two decades, supported more than 1,900 innovators and companies in the life sciences sector.

Spread across a 200-acre, state-of-the-art green campus, IKP offers a robust ecosystem comprising world-class laboratory infrastructure, incubation and co-working spaces, competitive grant programs, seed funding, IP, regulatory & technology transfer support, and dedicated mentorship, all designed to accelerate the journey from idea to impact.

A cornerstone of IKP's current strategy is internationalisation, fostering cross-border collaborations for co-development, co-funding, and market access. By bridging Indian innovation with global partners, investors, and ecosystems, IKP is enabling the creation of scalable, inclusive, and sustainable solutions with global relevance.

IKP welcomes international partners to collaborate and co-create transformative innovations that positively impact the planet.

Write to us at [engage@ikpknowledgepark.com](mailto:engage@ikpknowledgepark.com) to explore partnership opportunities.

To explore partnership opportunities: [engage@ikpknowledgepark.com](mailto:engage@ikpknowledgepark.com)

For more information, please visit [www.ikpknowledgepark.com](http://www.ikpknowledgepark.com)



## a One Health company

- 5 Bn doses produced till date
- 90 Mn doses of Human vaccines produced last year
- Touching 250000 Human lives everyday
- 492 Mn doses of animal vaccines produced last year
- Touching 13 Mn animal lives everyday
- Leadership in Human & Animal Health vaccines
- Multi product, multi dosage forms capability
- Multispecies viral & bacterial facility
- State of the art BSL3 facility
- 4 Manufacturing facilities globally

### Human Vaccine Portfolio

Hep A | Td | MR | Rabies | DPTiHepB | Hep B | DPT | TT



LEADERSHIP

AGILITY

ENABLER





**KHURANA & KHURANA**

An ISO 9001:2015 Certified Firm

KHURANA & KHURANA

Khurana & Khurana (K&K) is a leading IP, Commercial/Corporate, Tax, Banking, and Litigation/Arbitration Law Practice in India, and comprehensively undertakes legal representations of numerous Corporates ranging from Fortune 5 to Cutting-edge Start up entities through its core team of over 350 professionals spread across 15 offices in India, South-East Asia, and GCC. On the IP front, K&K represents several leading Global Entities by handling a portfolio of over 6000 new patent applications a year, and over 7500 new Trade Mark applications a year, making its experience in overall Portfolio Creation, Management, and Enforcement cutting-edge comprehensive and thorough.

K&K is strongly recommended by Chambers, Legal 500, Managing IP, IAM, Asia-IP, RSG, Acquisition-INTL, Corp-INTL, and Benchmark Litigation, and is also ranked as the highest PCT filing law firm in India along with several firm members being individually ranked for their litigation and prosecution practices. Apart from having multiple offices throughout India, K&K has several offices in South-East Asia with proudly over 60% women force along with direct representation in UAE/GCC, and therefore can directly represent clients in all such regions along with in other global territories through its strong network of foreign associates.

For more information, please visit [www.khuranaandkhurana.com](http://www.khuranaandkhurana.com)

Email address: [Tarun@khuranaandkhurana.com](mailto:Tarun@khuranaandkhurana.com)



Pharmaffiliates

CREATING OPPORTUNITIES

# CRDMO

1. Discovery Chemistry Support
2. Contract Research
3. Process Development
4. Contract Manufacturing
5. Custom Chemical Synthesis



## Other Services

- Reference Standards of Impurities, Metabolites, Nitrosamines, Deuterated compounds
- Analytical Research & Development
- SEED (Skill Enhancement & Education Development)



+91 82840 55580



pharmaffiliates.com



webenquiry@pharmaffiliates.com



# PopVax

Visit us at the  
India Pavilion:  
Booth Number  
**1065-C08**

## First-in-class and best-in-class mRNA vaccines and cancer immunotherapies using generative AI-enabled computational protein design


PopVax is an Indian full-stack biotechnology company developing novel mRNA vaccines and cancer immunotherapies using generative AI-enabled computational protein design. We have developed novel mRNA architectures for immunogen display, a lipid nanoparticle (LNP) delivery platform for mRNA using PopVax-designed novel ionizable lipids, and a machine learning-powered immunology feedback loop for vaccine and immunotherapy design. We are open to collaboration on vaccines and cancer immunotherapies, as well as out-licensing our novel ionizable lipids and LNP formulations. Our RNA Foundry service can take your novel RNA therapeutics from sequence to clinical trial doses, including process & analytical development and tox studies, in under 6 months.

[contact@popvax.com](mailto:contact@popvax.com)


<https://popvax.com>



Generative AI-powered high-throughput immunology feedback loop for vaccine and immunotherapy design



Library of 600 novel ionizable lipid designs, with 1000s of LNP formulations tested *in vitro* and *in vivo* – PopVax LNPs are non-toxic and perform equivalently to market-leading LNPs for vaccine delivery in rodents



mRNA-encoded immunogen display architecture that boosts the breadth and potency of the elicited immune response (>250x increase in Ab titer in mice)



**RNA Foundry:**  
Fast-turnaround GMP manufacturing and comprehensive analytical + QC platform that allows us to rapidly advance novel mRNA biomedicines to clinic end-to-end

Unprecedented speed & scale of testing: in just 3 years, we have –

Synthesized **110+** novel ionizable lipids

Tested **2000+** unique LNP formulations

Injected **1000+** unique vaccine designs in mice

Performed **15000+** immunoassays

### Key funders & sponsors

BILL & MELINDA GATES Foundation



**balvi**  
(Ethereum co-founder Vitalik Buterin)



Won **\$20M+** in non-dilutive funding over 3.5 years



# Prescience Insilico

Applying DeepTech to Scientific Research



Prescience Insilico is transforming the innovation roadmap for digital R&D. By leveraging advanced AI, machine learning, and physics-based simulations, we accelerate product development, reduce experimentation cycles, and drive sustainable innovation across sectors.



## PRInS<sup>3</sup>® - Prescience Drug Discovery Platform

Deep-tech enabled Software Platform for drug discovery & screening

BioIn ChemIn SyMoG/AI X-HTVS X-ESS



## Digital Scientific Services (R&D)

- Integrated physics and AI/ML-based digital R&D services with a strong focus on smart materials and specialty chemicals research
- Expertise includes novel material compositions, formulations, advanced chemistry, bespoke property optimization and beyond

FORMULATIONS

MATERIALS  
DISCOVERY

CHEMICALS &  
ENERGY

DRUG  
DISCOVERY



## Proprietary Platform Technologies

- AI based QSA/PR, AI-ADMET, BBB, permeation and solubility prediction
- Active library of drug-like compounds for more than 50 kinases
- Digital twin for Skin, Hair, Oral care, home care formulation and microbiome



## Prescience- Digital Transformation for R&D

- Development of customized analysis tools, web tools, image processing tools, & pipelines
- Built for scientific IR&D, offering AI/ML capabilities, access control, authentication, and an admin console for streamlined management
- Accelerate discovery through your data

## WHY CHOOSE US?

**Innovative Solutions:** AI-driven, precise, and efficient computational R&D services

**Collaborative Approach:** Accelerate innovation and achieve sustainability goals through scientific partnership

+91 6361546737 support@prescience.in www.prescienceinsilico.com



SURYA OFFICE SPACE, WHITEFIELD, 72/12, NALLURAHALLI MAIN RD, BENGALURU, KARNATAKA, INDIA- 560066

# Provis

Empowered by Science



## PROVINASE®

**Our flagship product for efficient and reliable  
Nucleic Acid removal**

**Advancing Biomanufacturing with Recombinant Bioreagents**

### Bio API products

L-Asparaginase Bulk  
Pegaspargase Bulk  
Streptokinase Bulk  
Semaglutide Bulk  
(Recombinant)

### Recombinant Bioreagents

Provinase®  
(Endonuclease)  
Carboxypeptidase B  
PNGase F  
Human Albumin  
Trypsin  
Kex2 Protease  
Enterokinase

### Peptide APIs

Semaglutide  
(Synthetic)  
Tirzepatide  
Leuprolide Acetate  
Desmopressin  
Acetate  
Octreotide Acetate

### CDMO/CMO Services

Clone development  
Process  
development  
Formulation  
development  
Large scale  
manufacturing

**BULK SUPPLY | GMP MANUFACTURING | CUSTOM OEM**

### STATE-OF-THE-ART GMP FACILITY

- Purpose-Built for GMP-Grade Proteins
- Seamless transition from RUO to GMP
- Scalable processes to meet growing global demand
- End-to-end supply chain support



**Provis Biolabs**  
Hyderabad, Telangana, India

11 Apex Drive Suite 300A,  
#157 Marlborough, MA 01752, USA



[bdusa@provisbiolabs.com](mailto:bdusa@provisbiolabs.com)



Provis Biolabs



[www.provisbiolabs.com](http://www.provisbiolabs.com)

## Shilpa Biologicals Pvt Ltd

Shilpa Biologicals is one of the largest fully integrated CDMO supporting end to end Drug Discovery, Development, GMP Manufacturing, Fill-Finish and Packaging solutions for NBE's, Biosimilars, ADC's and Vaccines. Our strong scientific expertise with focused approach is dedicated to bringing molecules from lab to market in short lead time providing cost effective solutions.

### Our Expertise

#### Our Team

- 300+ years of cumulative experience
- 120+ dedicated team
- Highly qualified team with PhD's and Post-Doc's
- Strong QA, QC and Regulatory team

#### Experience

- Completed multiple projects
- mAb's & Non mAb's Ratio - 50:50

#### Our Technologies

- Perfusion System
- AKTA Pilot Chromatography System
- Screening clones using AMBR
- Huge capacities to handle large scale commercial production
- Three independent fill finish suites with automated filling lines

### End-to-End CDMO Solutions

Cell Line Development	Process Development	Drug Substance	Drug Product
<ul style="list-style-type: none"> <li>• Developability studies</li> <li>• Gene/Plasmid synthesis</li> <li>• Stable pool, RCB</li> <li>• Mammalian and Microbial platform</li> <li>• CHO DG44, CHO S, CHO ZN, CHO K4, CHO GS etc.,</li> <li>• Pichia &amp; E.coli</li> <li>• Analytical development, comparative studies, Bioassays &amp; Developability studies</li> </ul>	<ul style="list-style-type: none"> <li>• Upstream process development</li> <li>• Downstream process development</li> <li>• Pre-Formulation development</li> <li>• Analytical development</li> </ul>	<ul style="list-style-type: none"> <li>• MCB &amp; WCB preparation and characterization</li> <li>• Viral clearance studies</li> <li>• Tox batch - 50L &amp; 200L scale</li> <li>• DS Process validation</li> <li>• DS Engineering batches</li> <li>• DS GMP batches - 50L, 200L, 1,000L &amp; 2,000L</li> <li>• DS stability</li> <li>• Microbial - 20L to 55,000L</li> </ul>	<ul style="list-style-type: none"> <li>• Formulation Dev</li> <li>• Process Characterization</li> <li>• DP Process validation</li> <li>• IND/BLA</li> <li>• DP Engineering batches</li> <li>• Fill-Finish</li> <li>• DP stability</li> <li>• Packaging</li> <li>• Regulatory support</li> </ul>



Website : [www.shilpabio.com](http://www.shilpabio.com)  
 Email:  
[madhav@vbshilpa.com](mailto:madhav@vbshilpa.com)  
[sridevi@shilpabio.com](mailto:sridevi@shilpabio.com)  
[ajay.gopaluni@shilpabio.com](mailto:ajay.gopaluni@shilpabio.com)





**SRM**  
INSTITUTE OF SCIENCE & TECHNOLOGY  
Attending to the needs of the future

SRM Institute of Science and Technology (SRMIST), was established in 1985 at Kattankulathur, Tamil Nadu, India. SRMIST is one of the top-ranking multi-disciplinary private universities in India. The Institute offers academic programs in six major Faculties namely, Engineering & Technology, Medicine & Health Sciences, Science & Humanities, Management, Law and Agricultural Sciences through 23 Schools, 116 Departments and 18 Centers of Excellence for Research, offering 109 UG and 145 PG programs. The BIRAC BioNEST at SRMIST focuses on nurturing early-stage biotech and healthcare startups by providing world-class infrastructure, technical mentorship, and access to high-end lab facilities to bring their ideas to market. The BioNEST at SRMIST is supported by the Centre for Clinical Trials and Research (CCTR) and the Division of Medical Research (DMR) providing a holistic validation to the healthcare products. The SRMIST's Directorate of Entrepreneurship (DEI) at Kattankulathur Campus promotes the entrepreneurship and innovation ecosystem. The DEI also manages the University's patent portfolio through the Centre for Intellectual Asset Protection (CIAP).

SRM Technology Transfer Office (SRM TTO) works with the inventors to commercialize the intellectual property. Bootstrappers' Research Council (BRC) which is registered as a Section 8 non-profit company, operates the university's incubator focusing on supporting startups through various critical stages including Pre-Incubation, Incubation, Fundraising, Mergers & Acquisitions, and Technology Commercialization.

For more information, please visit [www.srmist.edu.in](http://www.srmist.edu.in)

Email address: [director.dei@srmist.edu.in](mailto:director.dei@srmist.edu.in)



**SynSmart**  
Accelerating Discovery Solutions

## Service Portfolio

**Computational  
Chemistry**

**Medicinal  
Chemistry**

**Synthetic  
Chemistry**

**Process Research  
& Scale-up**

**Drug Substance  
Manufacturing**

**ADME-PK  
Services**

## Key Numbers : 2024



**10+**  
Years of business  
operations



**30+**  
Global Clients Across  
Key Markets



Trusted by **3** of the  
Top **10** Global Pharma  
Companies



**500+**  
Compounds Successfully  
Delivered



**100+**  
Highly Skilled Scientists  
& Chemists



**7,500**  
Sq. Ft. of Advanced  
Lab Space



**200 L**  
Reactor size in  
Kilo-Liters



**3,000 L**  
Reactor size at  
Manufacturing  
Site



**Innovating Chemistry, Accelerating Discovery**



bd@synsmartLin



www.synsmartLin



**SynSmart Rasayan Research LLC**  
21 Juniper Ct, Newtown, PA-18940



**SynSmart Rasayan Research Pvt. Ltd.**  
2<sup>nd</sup> Floor, W-372, Cross Rd Number 5, Sector 8, MIDC Industrial Area, Rabale, Navi Mumbai - 400701, Maharashtra, India.

## Guidance TamilNadu

Guidance Tamil Nadu is the investment promotion agency of the Government of Tamil Nadu, India's most industrialized state. With a robust and diverse industrial ecosystem, Tamil Nadu is advancing its biotechnology sector with a focused, mission-driven approach.

As a single-window facilitation body, Guidance offers end-to-end support to investors through a dedicated team of sector specialists, policy advisors, and international consultants. We streamline the investment journey by coordinating with industry stakeholders, community partners, and government departments—consolidating efforts to ensure a seamless and efficient business experience. In the life sciences sector, Guidance's primary objective is to position Tamil Nadu as the investment destination of choice.

## TICEL Biopark Limited

TICEL Biopark Limited, Chennai, Tamil Nadu, India is a state-of-the-art Biotechnology Park established in 2004 in Tamil Nadu, India. TICEL Biopark is promoted by TIDCO (Tamil Nadu Industrial Development Corporation) in technical collaboration with Cornell University, USA. TICEL Biopark supports Biotech ecosystem from their early stage of research to pilot-scale production by providing laboratory infrastructure and equipment support. Major companies such as Biocon biologics, Teva pharma, Levim biotech, Amway, Johnson & Johnson, Hi-yoshi India and Revvity Health sciences are located in Ticel Bio Park.

The Biotech Core Instrumentation Facility, housed at TICEL Biopark, provides equipment support to startups and industries. TICEL provides Laboratory infrastructure which supports to create GMP/GLP/ Contract Research (CRO) / Contract Manufacturing (CMO) / testing facility. TICEL undertakes contract research and contract manufacturing work at its Biotech Core Instrumentation Facility.

For more information, please visit [www.ticelbiopark.com](http://www.ticelbiopark.com)





VINAYAKA MISSION'S  
RESEARCH FOUNDATION

(Chartered to the Government of India under section 2 of the SLS Act 1988)



**AVMC**  
AJAYAPPA VEDAI MEDICAL COLLEGE

# PIONEERING INNOVATION IN HEALTH AND MEDICINE



## Digital Health

Transforming healthcare through intelligent diagnostics, personalized treatments, and predictive analytics.



## Diagnostic Genetics & Biomarkers

Accelerating precision medicine through cutting-edge genomic insights and biomarker discovery.



## Medicinal Chemistry

From lead identification to optimization — crafting the molecules that matter.



## Clinical Research & Super Speciality Hospital

End-to-end clinical trial execution with a patient-first approach. Backed by state-of-the-art super speciality facilities.



SCIENCE DRIVEN, CUSTOMER FOCUSED



[www.vmrfd.edu.in](http://www.vmrfd.edu.in)

[www.avmc.edu.in](http://www.avmc.edu.in)



+91 98409 75643

+91 44 42989000



[parthi@vinayakamissions.com](mailto:parthi@vinayakamissions.com)



New No.213, Old No.160, Poonamallee High Road, Kilpauk, Chennai - 600 010, Tamil Nadu, India



**VIPRAGEN**

DELIVERING RESEARCH

Vipragen Biosciences is an OECD GLP, AAALAC, and NABL/ISO 17025 accredited preclinical Contract Research Organization (CRO), with 20,000 SFT State-of-the-art Vivarium located in Mysore, India. We offer pre-clinical contract research services to clients worldwide, specializing in In-vitro Biology, Toxicology, and Analytical Testing, adhering to regulatory standards such as US-FDA, EFSA, and TGA.

- ✔ Vipragen is a dynamic and adaptable preclinical CRO, providing comprehensive end-to-end services with a focus on agility and responsiveness to meet the unique needs of our clients.
- ✔ Our team consists of multi-disciplinary experts in In-vitro & In-vivo Pharmacology, Bio-analytical, ADME/DMPK, and Regulatory Toxicology.
- ✔ We are deeply committed to quality, integrity, and customer satisfaction. Our project management teams have extensive experience handling global client projects, consistently exceeding expectations.
- ✔ Our in-vitro team has established over 100 assays across various therapeutic areas, and we have more than 50 validated animal models in Oncology, CNS, Inflammation, Dermatology, Ophthalmology, and Immunology.
- ✔ We have conducted over 1000 toxicology studies for regulatory submissions, including Acute, Sub-acute, and Repeated dose (28 days, 90 days), Development and Reproductive Toxicology (DART) studies, and Genotoxicity studies.

To collaborate or learn more,  
[www.vipragen.com](http://www.vipragen.com)

# WHALE TANK BIOCATALYST

Accelerating Deep Tech Innovation for  
Global Health & Sustainability



## The Pheromone Revolution in Crop Protection

*Leveraging Synthetic Biology for affordability*

**Pheromone-based mating disruption over 100M hectares**

- Non-toxic crop protection and ag-biological innovations
- Disrupting pest life cycles to reduce pesticide dependence
- A global leader in sustainable agriculture biotech.



## Clean, Lean & Green Sugar Reduction Through Science

*Nature's Sweetest Secrets Engineered for Wellness*

- Functional sugar alternatives: FOS, Brazein, Allulose
- India's first synthetic biology-derived fiber range
- *Scaling health-positive sugars from India to the world.*



## Revolutionary One-Shot Vaccine for Obesity & Fatty Liver

*A First-in-Class Vaccine  
Targeting Fat Metabolism, Not Appetite*

- Activates fat burning & prevents liver fat accumulation
- No appetite suppression, no weight rebound
- UT-009 progressing from stellar preclinical data to human trials
- *A moonshot innovation for metabolic disease.*







**YASHRAJ**  
**BIOTECHNOLOGY LTD.**  
*a bio-quest for ever*

YASHRAJ BIOTECHNOLOGY

Established in 1999, Yashraj Biotechnology Ltd. (YBL), headquartered in Mumbai with offices in the US and Germany, is a pioneer in the In Vitro Diagnostics reagent space and an emerging CRO specializing in preclinical drug discovery.

Our core capabilities are in the manufacturing of Native and Recombinant Antigens, as well as Monoclonal and Polyclonal Antibodies that are used by most of the top IVD companies across the globe. Our more than 300,000 sq ft of research and manufacturing space allows us to be a partner to global companies in the diagnostics and life sciences space.

Our expertise also lies in developing human induced pluripotent stem cell (hiPSC)-based models and products for disease research, advancing human relevance in preclinical testing. Supported by a state-of-the-art GMP facility, YBL offers a comprehensive range of iPSC-derived products and services, including cell-based assays, drug screening, efficacy testing, safety profiling, and disease modeling. YBL has built a reputation for unwavering quality and reliability. This commitment to excellence drives our efforts to push the boundaries of translational research and accelerate the development of next-generation therapeutics.

For more information, please visit [www.yashraj.com](http://www.yashraj.com)

Email address - [raj@yashraj.com](mailto:raj@yashraj.com)

# Indo US Organization for Rare Diseases

Bridging Nations, Empowering RARE Lives

## Our Initiatives



## Our Impact

<b>65</b>	<b>157</b>	<b>20,000+</b>
Patients Alliance Members	Patients Supported	Patients Connected
<b>38</b>	<b>20</b>	
Events Hosted	Global Partnerships	

## JOIN US AT Indo US Bridging RARE Summit 2025

Date:

November 2-4, 2025

Location:

Hilton Performing Arts Center,  
George Mason University, Manassas, VA

[summit.indousrare.org](https://summit.indousrare.org)

#bridgingrare



## Association of Biotechnology Led Enterprises

Association of Biotechnology Led Enterprises - ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector.

ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers.

The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector.

ABLE Council of Presidents, that comprises of all past presidents of the organization, has been set up to provide impetus to the growth of the Biotech business ecosystem to leverage their multi-sectoral expertise. ABLE thus catalyses a symbiotic interface between the industry, the government, academic and research institutes and domestic and international investors.

To collaborate or learn more,  
[www.ableindia.in](http://www.ableindia.in)



# LET SCIENCE DO THE TALKING



## From Targets to Drugs

Curadev is a clinical stage biotech company, dedicated to discovering and developing novel small molecule therapeutics for the treatment of intractable diseases.

Utilizing a target-centric approach, innovative screening schemes and traditional wet-lab chemistry and pharmacology, Curadev has built an impressive portfolio of discovery research programs, resulting in patent-protected drug candidates that modulate next-generation drug targets.

## Areas of Interest

Our programs seek to ameliorate disease by translating cutting edge discoveries into new medicines.



Runaway Immune Responses



Vaccine Adjuvants



Immune Oncology



Acetate Metabolism



Neuroscience

## Visit us



<https://www.curadev.in>



[interact@curadev.in](mailto:interact@curadev.in)



<http://www.linkedin.com/company/curadev>



<https://twitter.com/CuradevPharma>



**CURADEV**

*Let science do the talking*

**INERA**<sup>®</sup>  
by absolute

# Breakthrough Bio-enabled Farm Inputs

Biocontrols | Seedcoating | Biostimulants | Biofertilisers

RNA, Peptide and  
Enzyme Based Products

**2.5 Mn+**

sq. ft R&D setup

**8.5 Mn+**

Farmer lives impacted

**9+**

Proprietary  
Technologies



[www.inera.ag](http://www.inera.ag)